Located in Altamonte Springs, Cord For Life® Inc. is a local umbilical cord blood bank that specializes in public and private stem cell processing and cryopreservation. Cord For Life® has operated in the Central Florida area since 1993, and to date has processed over 15,000 cord blood units from across the United States. In addition to collecting, processing and banking umbilical cord blood stem cells, the company provides consulting services to help organizations develop and operate high-quality cord blood banks, and offers educational training programs for healthcare professionals.

Recently, Cord For Life® launched its cord blood banking program.  Under this program private clients can store their baby’s cord blood stem cells (CBSC) for future needs or moms-to-be can donate their baby’s cord blood to the general public through the National Marrow Donor Program’s (NMDP) Be The Match® Registry. Public donation, which has no cost to the donor, makes CBSC available to anyone in the world in need of a stem cell transplant to treat over 75 diseases.

The Cord For Life® program utilizes a revolutionary new processing system, branded as PREMIERMAX®, which significantly reduces red cell contamination in the transplant product while recovering an equal or higher number of stem cells (when compared to other automated and traditional methods). PREMIERMAX® also reduces the level of DMSO required to adequately preserve the cells during the freezing process, thereby reducing potential recipient exposure to this sometimes toxic cryoprotectant.

PREMIERMAX® uses 2 unique reagents combined with individual unit Quality Control by highly trained technicians, to produce a superior final transplantation product. The processing reagent is PrepaCyte®-CB, which demonstrates an unrivaled ability to remove red blood cells over any other method on the market today. Red cell reduction reduces the amount of free hemoglobin in the thawed product infused to the recipient, thereby increasing the safety of the infused product. Additionally, PrepaCyte®-CB has shown in clinical trial and independent evaluation to increase the final stem cell population recovered, most significantly in the post-thaw colony forming assay which indicates functionality of the stem cells for engraftment.

The second key reagent in PREMIERMAX® is the freeze media, CryoStor® CS10. CryoStor is specifically designed to protect cells at ultra-low temp e r a t u r e s , unlike traditional cryopreservation reagents. This results in improved cellular transition through phase change from a liquid blood product to the frozen state for long-term storage, and again during thawing prior to infusion. During our validation of CryoStor® CS10, it was demonstrated that a less concentrated amount of the cryoprotectant reagent DMSO could be used in the freezing process while maintaining acceptable cellular functionality post-thaw.

The most important aspect of any change in status quo is the resulting effect of the change. Historically, the lower stem cell dose of a CBSC product when compared to a bone marrow or peripheral blood stem cell collection resulted in a longer time for bone marrow reconstitution (or engraftment). This led to early beliefs that CBSC could only be useful for pediatric patients or small adults. It was also realized that CBSC would typically result in longer periods of non-immunity, resulting in longer hospital stays for the recipient, even though GvHD is typically reduced.

Current data from over 20,000 CBSC transplants worldwide, shows an average time to PMN engraftment (PMN cell count >500 for 2+ days) is 25-27 days. In fact, our own historical data shows a comparable average PMN engraftment time of 21 days for units processed before our change to PremierMax-CBSM. Following our change in processing method, we are currently seeing an average time to PMN engraftment of only 11.33 days. Even more exciting is that independent data from another NMDP member cord blood bank that also uses PrepaCyte®-CB as it’s processing reagent mirrors our data from Cord For Life® (poster abstract to be published at AABB Annual Meeting 22-25 Oct., 2011).

As you can appreciate, a nearly 10 day reduction in the length of hospital stay, especially for a critically ill patient with no immune function, is highly significant. Having a readily available stem cell source product that can rival the engraftment time of marrow or peripheral blood sources, with a reduced risk of GvHD, and a significantly increased HLA-matching potential would create a major shift in the paradigm. Cord blood products have already begun to outpace marrow as a source for stem cell transplantation. With significant results such as these and new, exciting therapies being developed worldwide, the usefulness of cord blood stem cells will only increase over time. As more and more PREMIERMAX® processed CBSC units are transplanted worldwide, Cord For Life® will continue to monitor and analyze the engraftment data. A 2-site joint publication is expected in 2011 to further analyze the significance of the findings over a broader range of CBSC units, diseases, and transplant centers to eliminate other possible factors for the decreased engraftment time. We feel this finding could create a new excitement in the cord blood transplantation industry and provide a remarkable benefit to patients in need of life saving stem cell transplants.

By Donald Hudspeth, BS(CLS), MT(ASCP) and Sara Irrgang, MD, FCAP, FLORIDA MD, September 2011 Edition, pgs 33-34



December 2, 2016


Cord For Life® has been accepting umbilical cord blood collections for private storage and public donation for over 15 years. Until recently, Cord For Life® was the only cord blood center that collected from national non-fixed sites (NFS) and fixed sites (FS) facilities. With others in the industry expanding to NFS collections, we compared our FS collections using Cord For Life® trained MDs, midwives, and collection staff to our national NFS collections to identify the strengths and weaknesses of the two programs.


The comparison was performed on all collection data from the years 2009 – 2010 where current acceptance criteria were constant. Using data entered in the StemSoft database system, the analysis examined total units received vs. registry placement and privately stored vs. publicly donated collections.


From the total donated units received 26% of FS collections were processed and placed on a registry. For NFS the total donations processed and placed on the registry was only 10%. Privately stored collections were 12% higher from the NFS while FS had 18% higher publicly donated units. The primary cause for unit rejection was low pre-TNC count (<12×108) often directly related to product volume. Excluding the pre-count the following were the next highest reasons for rejection:


Fixed site collections allow for stronger management and control resulting in a more efficient and successful collection. There is a significant advantage in decreasing “preventable” errors and overall optimizing collections. There are many challenges to consider before implementing a non-fixed site collection program.

Although a greater number of units were received from the non-fixed locations, the overall product quality is lower. Another consideration is timing; kit shipment to the client prior to labor and unit receipt at the laboratory can impact the ability to meet the regulated timelines.

Using monthly tracking data as a CPI tool we discontinued acceptance of weekend collections as “normal” courier service is limited. This change resulted in fewer units received >48 hours from collection, saving collection materials and shipping costs. Other findings include lower efficiency and higher per banked unit cost in the NFS model.

Success of a non-fixed collection program will rely on improved distance training, increasing efficiency to improve value and there must be an outlet for non-transplantable units. Visit us at or call 800-869-8608 for more information.


January 18, 2012

When you hear the term “stem cells”, what comes to mind? Religious controversy? Ethical debate? embryonic stem cell research? These associations are common, and unfortunately could be limiting how often stem cells are donated for use as a life-saving transplant.

Many people equate stem cells with embryonic stem cell research but non-embryonic (or adult) stem cells are different and they’re used every day in modern medicine to save lives. Furthermore, to date, embryonic stem cells have not been used for many human therapeutic purposes.

Nearly everyone knows someone that has had or needed a bone marrow transplant, but did you know that the transplant is actually of a type of stem cell? There are several types of adult stem cells that are far removed from their controversial embryonic cellular parents. Adult stem cells can be found in the bone marrow, peripheral blood, umbilical cord blood, fat tissue, teeth and many other sources.

Over 100,000 stem cell transplants have been performed in the U.S. Bone marrow was first used in the late 1960’s for transplants to combat leukemia, lymphoma and other blood diseases. In the late 1980s, the first transplant using umbilical cord blood stem cells was performed. The success of this first cord blood transplant has led to several thousand more patients being treated with stem cells. Additionally, adult stem cells are being used in the field of regenerative medicine to further develop uses for these special cells in fighting other diseases.

The beauty of umbilical cord blood stem cells is that these cells are collected from what was once considered medical waste. After the normal delivery of a baby, the umbilical cord is clamped and cut, and about 150mL of cord blood remains in the cord. This cord blood is rich in stem cells that can be used as an alternative to bone marrow stem cells for transplantation. These stem cells from the cord blood can be used for treating more than 75 diseases.

In addition to the easy and non-invasive collection process for cord blood, these cells offer a few advantages over bone marrow stem cells when used for transplantation. Stem cells from cord blood are biologically much less mature than those from bone marrow of an adult donor. If we think of the immune cells as “warriors,” the “warriors” found in the adult marrow donor sample are fully capable of fighting and therefore a common problem in a bone marrow sourced stem cell transplant is graft vs. host disease (or GVHD). GVHD occurs when the donor cells attack the recipient cells and tissue as foreign. This can cause a very severe problem for transplant recipients and is a form of reverse rejection.

With cord blood sourced stem cell transplants, GVHD is typically far less prevalent and far less severe. This is because the “warriors” are less mature. The cells are not as capable of fighting. This is the same reason that newborn babies often constantly battle sniffles and colds; their immune system cells are not yet fully functional.

In the transplant setting, having these functionally immature immune cells allows the matching between donor and recipient to be less important. In a bone marrow source transplant, the donor must perfectly match the recipient, whereas in a cord blood sourced transplant, a less-perfect match can be used with similar success. This leads to more patients being able to find a suitable stem cell source for their needed transplant. According to recent data from the National Marrow Donor Program (NMDP), non-Caucasian recipients in need of transplant are more likely to find suitable matches of cord blood stem cells than from adult marrow donors.

You can donate your cord blood for free or privately store it for a fee through the Altamonte Springs-based Cord For Life®. Because of cord blood, many more people, especially non-Caucasians, can receive the life-saving treatment they desperately need.

Winter Park/Maitland Observer


Our purpose is to provide the expectant mothers with information necessary to discover the lifesaving potential of umbilical cord blood.

Copyright Cord for Life 2019. All rights reserved.


Mr. Kondorosi has been involved with the hospitality and hotel industry for most of his life.  From 1969 through 1985, he held various positions at the international InterContinental Hotels chain, including various senior management roles.  After his transitioning to the USA, he moved into the real estate business and held a variety of positions.  Recently he has held te position of Director of Sales for Prestige Homes, Inc. part of Goldrich and Kest Industries headquartered in California since 1957.  Mr. Kondorosi represented the successful sale of 386 homes in the Bel Air Crest Development, including re-sales over the past several years, various high end listings and sales in prominent locations such as Malibu, Pacific Palisades, Bel Air, Beverly Hills and other parts of the west-side Los Angeles area.

Mr. Kondorosi is also the founder and President of EDKO Trade, Inc., and international real estate and trading company involved in promoting and closing transactions between various companies and individuals located around the world.  Since 2000, he has also been involved in various international and foreign innovative startup companies in various capacities including CEO, board member or in a consulting role.  Mr. Kondorosi received a Juri Doctor degree from Janus Pannonius University in Hungary in international law.  He also was a professor at the Budapest Business School / Faculty of Commerce, Catering and Tourism in Hungary.

In addition, Mr Kondorosi has served on the Board for the Regency Club from 2008 through 2011, a private business organization started by David Murdock 30 years ago in Los Angeles.

Deborah A. Sardone

Ms. Sardone has over 30 years of clinical laboratory experience as a Clinical Laboratory Technologist, including over 25 years with Central Florida Regional Hospital (CFRH). She was Supervisor of Quality Assurance, Safety and Education at CFRH for 11 years, held the positions of Blood Bank Supervisor for 11 years, and Hematology Supervisor for 1 year. She has participated in both sides of the inspection process, serving on the College of American Pathologists Inspection team for CAP Hospital Accreditation in Florida, and assisting in receiving accreditation by The Joint Commission (TJC), American Association of Blood Banks (AABB), and Food and Drug Administration (FDA) through the inspections of the clinical laboratory.

Ms. Sardone is licensed by the State of Florida as a Clinical Laboratory Technologist in Immunohematology, Hematology, Serology and Clinical Chemistry. She is a certified Clinical Laboratory Technologist with the American Society of Clinical Pathologists (ASCP).

Ms. Sardone serves as Manager of Quality Assurance and Regulatory Affairs at Cord For Life®, Inc. overseeing all licensing and regulatory agencies to ensure that the highest quality in all aspects of cord blood collection, processing, and storage is maintained.

Ms. Sardone’s skills and knowledge in blood banking and quality assurance have enabled her to establish, implement and maintain a superior quality system that meets and exceeds all standards and regulatory requirements for Cord For Life®, Inc.

Personal Background:

  • Sardone is a graduate of The City University of New York in Medical Laboratory Technology.
  • Sardone is licensed in Florida as a Clinical Medical Technologist and she is nationally recognized as ASCP Certified.
  • Sardone enjoys photography and dancing.

Donald Hudspeth

Mr. Hudspeth has over 17 years of clinical laboratory experience as a certified Medical Technologist (ASCP), including ten years with the University of North Carolina Hospitals. Mr. Hudspeth is licensed by the State of Florida as a Clinical Laboratory Supervisor in Immunohematology, Hematology, Serology, Clinical Chemistry, Molecular Pathology and Microbiology as well as a Clinical Laboratory Scientist, is a registered Technologist with the American Society of Clinical Pathologists and a member of the American Society of Blood and Marrow Transplantation (ASBMT).

He has also enjoyed teaching Immunology to Clinical Laboratory Science and medical school students at UNC while working in the UNCH clinical labs. At Cord For Life®, Mr. Hudspeth serves as Chief Operating Officer, overseeing all operations and the daily laboratory operations to ensure that the highest quality in all aspects of donor selection and cord blood collection, processing, and storage is maintained. He also works with Quality Assurance to ensure full compliance by Cord For Life® to all applicable regulations. Mr. Hudspeth has sat on numerous cord blood focused committees and advisory groups.

Additionally, Mr. Hudspeth served as the Clinical Investigator for Cord For Life® as they evaluated and approved a new processing methodology to isolate stem cells from cord blood while depleting the unwanted red cells. Mr. Hudspeth works with groups, individuals, or government agencies to bring cord blood banking to countries around the world. He is responsible for training medical professionals worldwide in cord blood processing at our Florida location. In addition, he travels overseas to assist in the initial setup and implementation of the new facilities to ensure their compliance and quality. Mr. Hudspeth has assisted in opening new cord blood facilities in Europe and in SE Asia.

Personal Background:

  • Mr. Hudspeth received his Bachelor’s degree in Clinical Laboratory Sciences from the University of North Carolina at Chapel Hill.
  • “Eagle Scout with Five Palms”
  • Avid golfer with a 14 handicap.

Donald R. Drake III, Ph.D

Don joined Sanofi Pasteur VaxDesign in 2005 and has served as Director of Immunological Research since 2009. He has had a long-standing interest in the immune system, particularly the interaction between viruses and elements of the adaptive immune system, since initiating his graduate studies at Emory University in Atlanta, GA.

As a post-doctoral fellow at the University of Virginia, he was awarded funding from the Cancer Research Institute and received an Interdisciplinary Training Grant in Immunology from the National Institutes of Health to study CD8+ T cell immunity against influenza virus.

At VaxDesign, Don leads a team developing and optimizing the MIMIC® System to permit the evaluation of human adaptive immunity (cellular and humoral responses) against vaccine candidates, biologics, and other immunomodulators in a pre-clinical setting. He is an author on a variety of patents and peer-reviewed journal publications.

Kelli Cable

Mrs. Cable brings over 20 years of experience to Cord For Life® directing the Client Services, Account Management and Personnel departments. She began working in the cord blood industry in December of 2006. In addition, Ms. Cable is actively involved in marketing for the company.

Personal Background:

  • Mrs. Cable is married and has two boys.
  • In 1994, Ms. Cable moved to Orlando from Boulder, Colorado.
  • Has a passion for travel and enjoys watching NFL games, cheering on her favorite team, the Denver Broncos.

Richard R. Gammon, M.D.

Dr. Richard R. Gammon joined Florida’s Blood Centers (FBC) in 2005 and is responsible for ensuring that the organization’s medical practices, policies and testing remain at the forefront of the blood-banking industry. He received his undergraduate degree from Gannon University in Erie, Pennsylvania and medical degree from Hahnemann University in Philadelphia.

He completed his residency at The Ohio State University and his fellowship at the University of Virginia. He also serves as an assistant professor of pathology at the University of Central Florida College of Medicine. He has served as President and Technical Committee Chair of the Florida Association of Blood Banks. He currently serves as the Chair of the Scientific Medical and Technical Committee and Chair of the Journal Club for America’s Blood Centers.

He is an assessor and abstract reviewer for AABB and is a manuscript reviewer for the journal Transfusion. He is the co-recipient of a 2011 ABC Foundation Grant for the Get Healthy Wellness Program. Dr. Gammon’s research has been published in various peer-reviewed journals and he has been a featured speaker at numerous national and international conferences on blood banking and transfusion medicine.

Robert Parkhill, Ph.D

Dr. Parkhill directs operations at the Sanofi Pasteur VaxDesign Campus, which designs, develops, and manufactures in vitro models of the human immune system. Their mission is to prevent infectious disease by forecasting vaccine responses before clinical trials, and create a competitive advantage by providing predictive in vitro immunological models and assays. Dr. Parkhill holds a PhD in Material Science and Inorganic Chemistry for Oklahoma State University.

Robert W. Pollack, M.D., R. PH.

Dr. Pollock was originally from Ohio where he majored in pharmacy at Ohio Northern University. After graduation he worked as a pharmacist and attended The Ohio State University where he majored in chemistry and graduated in biochemistry.

In 1992 he attended Wright State University School of Medicine in Dayton Ohio, after graduating from medical school he completed his residency at Orlando Regional Medical Center in anatomic and clinical pathology, then a two year fellowship in clinical molecular genetics at All Children’s Hospital in St Petersburg Florida. After completing his fellowship in genetics, he became Medical Director for Central Florida Blood Bank for 3 years where he took great interest in the stem cell donation program.

After leaving the blood bank, Dr Pollock became Assistant Director in Molecular Genetics for the Centers of Advanced Diagnostics which at the time was a division of Ameripath. After the restructuring of the Orlando operation, Dr Pollock found himself back in blood banking. He was medical director for BloodNetUSA in Lakeland, Florida prior to its merger with Florida Blood Services.

Sara Irrgang, M.D

During the last two years of Medical School, Dr. Irrgang was in the United States Navy 1915 Ensign Program and completed a clerkship at the Naval Hospital at Charleston, South Carolina as well as a research clerkship at the Naval Aerospace Institute at Pensacola, Florida.

Dr. Irrgang completed her four year Pathology residency at Baylor University Medical Center, and her internship at the University District Hospital, Rio Piedras in San Juan, Puerto Rico. Currently, Dr. Irrgang is Board Certified in Anatomic and Clinical Pathology and licensed in the states of South Carolina, Texas, New Jersey and Florida and she is an Associate Medical Examiner at the District Nine Medical Examiners Office.

Dr. Irrgang is a fellow at numerous organizations including; The College of American Pathologists, National Association of Medical Examiners, Florida Association of Medical Examiners, Seminole County Medical Society, and the Florida Medical Society.

Personal Background:

  • Dr. Irrgang received a Bachelor of Science degree in Pharmacy from the University of South Carolina.
  • Attended the Medical College of South Carolina at Charleston where she earned a Medical Doctorate Degree.
  • Dr. Irrgang has a passion for breeding show horses
  • Dr. Irrgang is a 4-H leader in Lake County, Florida

Tisha M. Foster, M.D

Dr. Tisha M. Foster joined Florida’s Blood Centers (FBC) in 2008 and is responsible for therapeutic apheresis, cellular therapies, and FBC’s participation in the National Marrow Donor Program. She received her undergraduate degree from the University of Central Oklahoma and her medical degree from the University of Oklahoma. She completed her residency at the University of Oklahoma Health Sciences Center and her fellowship at the Medical College of Wisconsin/Blood Center of Wisconsin. Prior to joining FBC, Dr. Foster served as medical director at BloodNetUSA in Lakeland (Fla.), where her responsibilities included supervision of the Transfusion Service Laboratory at Lakeland Regional Medical Center, donor eligibility, therapeutic apheresis, and ensuring regulatory compliance throughout the blood center.